Investment Rating - The report assigns an "Overweight" rating for the industry, indicating an expected performance that exceeds the Shanghai and Shenzhen 300 Index by more than 15% [4][10]. Core Insights - The report highlights the five-year follow-up results of Moderna's personalized mRNA cancer vaccine V940 in high-risk melanoma, supporting the vaccine's mechanism to provide durable immune responses, which strengthens the clinical basis for subsequent Phase III and registration advancements [2][5]. - The KEYNOTE-942 study results show that the combination of V940 and Keytruda reduces the risk of recurrence or death in high-risk melanoma patients by 49%, with efficacy maintaining from 44% at the two-year follow-up to 49% at the three-year and five-year follow-ups, without new safety signals being reported [5]. - V940 is advancing ahead of similar projects, with eight ongoing Phase II/III clinical studies covering various solid tumors, including melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma. The Phase III trial for melanoma has completed enrollment and is expected to yield critical data in 2026, with the project also receiving FDA breakthrough therapy designation [5]. Summary by Sections - **Investment Highlights**: The report emphasizes the sustained efficacy of V940 in inducing durable immune responses, differentiating it from previous unsuccessful cancer vaccine attempts, and providing long-term clinical data support for mRNA tumor vaccine technology [5]. - **Clinical Data**: The report details that V940 can encode up to 34 new antigens, activating T-cell responses with immune memory characteristics, complementing PD-1 inhibitors [5].

Core Viewpoint - Recordati has entered into a collaboration and license agreement with Moderna to develop and commercialize mRNA-3927, an investigational product for treating propionic acidemia, leveraging Moderna's mRNA technology and Recordati's commercial infrastructure [1][6]. Group 1: Collaboration Details - The agreement stipulates that Recordati will pay Moderna an upfront payment of USD 50 million, with potential additional payments of up to USD 110 million based on development and regulatory milestones [4]. - Recordati will lead global commercialization efforts if mRNA-3927 is approved, while Moderna will continue to lead its development [1][4]. Group 2: Product Overview - mRNA-3927 is designed to restore propionyl-CoA carboxylase (PCC) enzyme activity in patients with propionic acidemia, a rare inherited metabolic disorder characterized by toxic metabolite buildup [2][9]. - Interim clinical data published in Nature indicates early signs of clinical improvement, with a potential data readout expected by the end of 2026 [3][10]. Group 3: Market Context - Propionic acidemia affects approximately 1 in 100,000-150,000 individuals globally and currently lacks effective therapies targeting the underlying cause [7]. - If approved, mRNA-3927 could be the first disease-modifying treatment option available for this severe condition [2][6]. Group 4: Company Background - Recordati is an international pharmaceutical group with a focus on specialty and primary care, operating in around 150 countries and employing over 4,500 people [11]. - The company aims to address both common health challenges and rare diseases, emphasizing the belief that health is a fundamental right [11].

Core Viewpoint - Moderna has entered a strategic collaboration with Recordati to advance its investigational therapeutic mRNA-3927 for propionic acidemia through clinical development and global commercialization [1] Group 1: Collaboration Details - Moderna will lead the clinical development and manufacturing of mRNA-3927 [1] - The collaboration will provide Moderna with up to $160 million in upfront and near-term development and regulatory milestones [1] - Additional financial incentives include commercial and sales milestones, as well as tiered royalties on net sales [1] Group 2: Partner Information - Recordati is an international pharmaceutical group based in Milan, Italy [1] - The company specializes in treatments for specialty and primary care, as well as rare diseases, including propionic acidemia [1]

Moderna, Inc. (NASDAQ:MRNA) is one of the stocks Jim Cramer was recently asked about. Noting that the company is working on a cancer vaccination, a caller asked if they should invest in the stock. Cramer replied: Well, I gotta tell you, this is something that they did promise a long time ago, and I hope that it’s for real… I do say that we have to wait and see. Why? Because the stock’s up so much, 54% for the year. I just want to know how certain things really are. Photo by Ian Hutchinson on Unsplash ...

Core Viewpoint - Moderna has faced challenges in maintaining revenue growth from its coronavirus vaccine but has shown a strong start in 2026 with a 58% increase in stock price, raising questions about a potential sustained bull run for the company [1]. Group 1: Recent Developments - Moderna's recent data from a five-year follow-up study on intismeran autogene, in combination with Merck's Keytruda, demonstrated a 49% reduction in disease recurrence or death for advanced melanoma patients compared to Keytruda alone [3]. - Intismeran autogene is currently in a phase 3 study and is being investigated across multiple cancer types, with a total of eight phase 2 or phase 3 studies ongoing [4]. Group 2: Market Position and Opportunities - Moderna has established itself as a leader in mRNA-based therapies and the coronavirus vaccine market, with recent clinical progress and the launch of mRESVIA, a vaccine for respiratory syncytial virus [5]. - The partnership with Merck for intismeran autogene presents a significant commercial opportunity, potentially leading to blockbuster status, despite profit-sharing with Merck [6]. Group 3: Future Prospects - Moderna is expected to make sustained clinical and regulatory progress with several candidates in mid or late-stage clinical trials, which could diversify its lineup of approved products in the next three years [7].

Company Overview - Moderna is a commercial-stage biotech founded in 2010, with its IPO in December 2018. The company's mRNA technology gained rapid validation through its COVID-19 vaccine, authorized in the U.S. in December 2020. As of August 2025, Moderna has 35 mRNA development candidates in clinical studies across various therapeutic areas, including infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases [8]. Market Sentiment - Recent options trading indicates a bearish sentiment among deep-pocketed investors towards Moderna, with 55% of notable options leaning bearish and only 33% bullish. This shift in sentiment is significant and suggests that market players should pay attention [1][2]. - The total options activity for Moderna has been extraordinary, with 12 put options totaling $1,840,896 and 6 call options amounting to $311,479 [2]. Price Targets and Trading Activity - Whales have been targeting a price range for Moderna between $30.0 and $50.0 over the last three months, based on the volume and open interest of options contracts [3]. - The average open interest for Moderna options is 531.31, with a total trading volume of 9,720.00. The trading activity has been concentrated within the strike price corridor of $30.0 to $50.0 over the past 30 days [4]. Recent Trading Data - Significant options trades include bearish put options with a total trade value of $1.1 million at a strike price of $42.00, and bullish put options valued at $300,000 with a strike price of $47.00. Additionally, there are neutral and bearish call options with varying trade values and strike prices [7]. Current Market Standing - As of the latest data, Moderna's trading volume is 3,713,575, with the stock price down by 2.71% at $47.39. Analysts have recently adjusted their ratings, with one expert from UBS revising the price target down to $34.0, indicating a neutral stance on the stock [10][11].

CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 13, 2026 to report its fourth quarter 2025 financial results, and provide a corporate update. ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.39% from January 19 to January 23, underperforming compared to the Wind All A index, which rose by 1.81% [3][8]. - Key segments such as offline pharmacies (up 9.66%), raw materials (up 2.41%), and pharmaceutical distribution (up 2.28%) showed positive performance, while medical R&D outsourcing (down 3.96%), chemical preparations (down 1.74%), and medical devices (down 0.7%) lagged behind [3][9]. - The personalized tumor vaccine is expected to trigger a significant shift in whole exome sequencing (WES) technology, with Moderna's mRNA personalized tumor vaccine showing a nearly 50% reduction in recurrence or death risk compared to Keytruda alone, based on five-year follow-up data [3][12]. - The report emphasizes the importance of high-quality WES data for the efficacy of mRNA personalized tumor vaccines, suggesting that once validated, WES will transition from an optional to a mandatory diagnostic tool, leading to a value reconstruction in the upstream sequencing industry [3][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from January 19 to January 23 showed a decline of 0.39%, underperforming the Wind All A index, which increased by 1.81% [8]. - Notable gainers included *ST Changyao (up 70.4%), Hualan Biological Engineering (up 32.2%), and Tianzhihang-U (up 27.7%), while major losers were Sunflower (down 37.5%), *ST Changyao (down 33.3%), and Luyuan Pharmaceutical (down 26.6%) [11][12]. Industry News and Key Company Announcements - On January 20, the National Healthcare Security Administration released guidelines for pricing medical services related to surgical and treatment auxiliary operations, which has garnered significant attention in the medical industry [11]. - Moderna and Merck announced that their personalized mRNA vaccine mRNA-4157, in combination with Keytruda, significantly improved recurrence-free survival in high-risk melanoma patients, reducing the risk of recurrence or death by 49% [12][13]. - GSK announced a $2.2 billion acquisition of RAPT Therapeutics, which includes a monoclonal antibody currently in clinical development for food allergies [15]. - The report highlights various companies' performance forecasts, including a projected net profit of -900 million to -995 million for Maiwei Bio, and a significant increase in revenue for JianKai Technology, with expected net profit growth of 101.09% to 121.20% [15][16].

Group 1: Stock Performances - Hecla Mining Company (NYSE:HL) gained 29.31% this week amid rising precious metal stocks due to geopolitical tensions and a weakening US dollar, with expectations of a Fed rate cut [1] - First Majestic Silver Corp. (NYSE:AG) increased by 26.57% this week, following the trend in precious metal stocks [1] - Venture Global, Inc. (NYSE:VG) jumped 21.6% this week after the ICC issued a final arbitration award in favor of the company against Repsol [2] - Moderna, Inc. (NASDAQ:MRNA) rose 17.44% this week due to positive results from a five-year follow-up of a Phase 2b melanoma vaccine trial [2] - New Gold Inc. (AMEX:NGD) gained 24.03% this week, supported by a recommendation from Glass Lewis for shareholders to vote in favor of a merger with Coeur Mining Inc. [3] - Coeur Mining, Inc. increased by 23.13% this week, also benefiting from the merger news with New Gold [3] - United Microelectronics Corporation (NYSE:UMC) jumped 13.82% this week, reflecting positive market sentiment [3] - Micron Technology, Inc. (NASDAQ:MU) rose 13.21% this week after an analyst initiated coverage with an Outperform rating [4] - Korea Electric Power Corporation (NYSE:KEP) gained 15.29% this week, contributing to the overall positive performance in the sector [4] Group 2: Company Guidance and Production - Iamgold Corporation (NYSE:IAG) produced 765,900 ounces of gold in 2025 and provided guidance for 2026, targeting production between 720,000 to 820,000 ounces [4]

格隆汇1月23日｜Moderna跌超3%，该公司不打算投资新的后期疫苗试验。 ...